The ability to change the genetic information of immune cells is a powerful tool for basic and clinical settings. CRISPR/Cas9 gene editing technology by providing an efficient approach has accelerated immune cell therapy of cancers. Lymphoid cancers comprise a wide array of disease including lymphoma, multiple myeloma and lymphocytic leukemia.

Here, we review therapeutic applications of the CRISPR/Cas9 technology for immune cell therapy of common lymphoid malignancies. We describe current and future therapeutic application of CRISPR/Cas9 technology with the focus on the production and applications of engineered hematopoietic and immune cells against lymphoid malignancies. Furthermore, we provide an overview of the possible challenges and optimization of CRISPR/Cas9 system for ex- and in vivo applications within recent years.

改变免疫细胞遗传信息的能力是用于基础和临床设置的强大工具。CRISPR / Cas9基因编辑技术通过提供有效的方法加速了癌症的免疫细胞治疗。淋巴癌包括多种疾病，包括淋巴瘤，多发性骨髓瘤和淋巴细胞性白血病。

在这里，我们回顾了CRISPR / Cas9技术在常见淋巴恶性肿瘤免疫细胞治疗中的治疗应用。我们描述了CRISPR / Cas9技术的当前和未来治疗应用，重点是针对淋巴恶性肿瘤的造血和免疫细胞工程化生产和应用。此外，我们概述了近年来CRISPR / Cas9系统在体外和体内应用中可能面临的挑战和优化。